Management of MSS RAS wt Metastatic Colorectal Cancer: Sidedness - PowerPoint PPT Presentation

Management of MSS RAS ‐ wt Metastatic Colorectal Cancer: Sidedness and Anti ‐ EGFR Retreatment Benjamin A. Weinberg, M.D. Assistant Professor of Medicine Lombardi Comprehensive Cancer Center Georgetown University

LEFT RIGHT Cancers for Disease Control and Prevention

Younger Individuals Tend to Have Left-Sided CRCs Weinberg et al. Oncology (Williston Park) 2017.

CALGB/SWOG 80405: KRAS wt Presented By Alan Venook at 2017 ASCO Annual Meeting

<br /> 80405: (KRAS WT) Overall Survival by Sidedness Presented By Alan Venook at 2017 ASCO Annual Meeting

80405 (KRAS WT): Overall Survival by Sidedness and Biologic Presented By Alan Venook at 2017 ASCO Annual Meeting

Right vs. Left Colon vs. Rectum Salem et al. Oncotarget 2017.

Right vs. Left Colon vs. Rectum Salem et al. Oncotarget 2017.

NCCN Guidelines 3.2019. JNCCN 2019.

NCCN Guidelines 3.2019. JNCCN 2019.

KRAS -WT: Right vs. Left Primary Tumors NCIC CO.17 Trial Brulé et al. Eur J Cancer 2015.

Loree et al. GI ASCO 2019.

Re-Challenging with anti-EGFR Therapy • May not work as well patients who progressed on anti-EGFR therapy previously (more useful in those who discontinued due to toxicity) • Need to ensure tumor is still RAS and BRAF wild type • COLOMATE (liquid biopsy)  PULSE study (panitumumab re-challenge)

Questions? • baw12@gunet.georgetown.edu • @benweinbergmd